Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02783040
PHASE1

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

To assess the influence of multiple doses of BI 425809 on single dose pharmacokinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)

Official title: A Study to Investigate the Effects of Multiple Doses of BI 425809 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin and Omeprazole) and a P Glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Male Subjects

Key Details

Gender

MALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

13

Start Date

2015-09-07

Completion Date

2015-10-30

Last Updated

2026-04-15

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Midazolam

DRUG

Warfarin

DRUG

Omeprazole

DRUG

Digoxin

DRUG

BI 425809

Tablet

Locations (1)

1346.22.1 Boehringer Ingelheim Investigational Site

Biberach, Germany